The FDA has approved naloxegol (Movantik – AstraZeneca), a pegylated derivative of the opioid antagonist naloxone, for oral treatment of opioid-induced constipation in adults with chronic noncancer pain. It is the only oral opioid antagonist approved for this indication in the US.
Once a month, JAMA selects for publication one article previously published in The Medical Letter.
Previous Publication: This article was previously published: The Medical Letter on Drugs and Therapeutics. September 28, 2015;57(1478):135-137.
©The Medical Letter Inc.
About The Medical Letter: The Medical Letter is a nonprofit organization that publishes biweekly new drug evaluations and treatment recommendations. The Medical Letter does not accept advertisements, gifts, grants, or donations. Financial support comes solely from sales of subscriptions, books, software, continuing education materials, and licenses.
Editors: Mark Abramowicz, MD, President; Gianna Zuccotti, MD, MPH, Vice President/Executive Editor; Jean-Marie Pflomm, PharmD, Editor in Chief